Dincer, M. Et Al. 2008. Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases. MEDICAL ONCOLOGY , vol.25, no.3 , 356-359.

Dincer, M., Altundag, K., Harputluoglu, H., AKSOY, S., CENGİZ, M., & Gullu, İ. H., (2008). Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases. MEDICAL ONCOLOGY , vol.25, no.3, 356-359.

Dincer, Murat Et Al. "Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases," MEDICAL ONCOLOGY , vol.25, no.3, 356-359, 2008

Dincer, Murat Et Al. "Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases." MEDICAL ONCOLOGY , vol.25, no.3, pp.356-359, 2008

Dincer, M. Et Al. (2008) . "Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases." MEDICAL ONCOLOGY , vol.25, no.3, pp.356-359.

@article{article, author={Murat Dincer Et Al. }, title={Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases}, journal={MEDICAL ONCOLOGY}, year=2008, pages={356-359} }